GCP
UTHR icon

Garda Capital Partners’s United Therapeutics UTHR Stock Holding History

Garda Capital Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,494
Closed -$548K – 581
2023
Q4 		$548K Buy
2,494
+1,329
+114% +$306K 0.05% 324
2023
Q3 		$263K Buy
+1,165
New +$268K 0.01% 651

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Garda Capital Partners's UTHR Position: Q1 2024 in Review

Garda Capital Partners sold out of United Therapeutics (UTHR) in Q1 2024, closing a stake of 2,494 shares — an estimated $548K sold.

Garda Capital Partners first reported a position in UTHR in Q3 2023 and held it in 2 quarters. The position peaked at $548K in Q4 2023. 526 funds tracked by Wall St. Rank hold UTHR as of Q1 2024.

  • Garda Capital Partners reported no remaining United Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Garda Capital Partners sold 2,494 United Therapeutics shares in Q1 2024, an estimated $548K.
  • Garda Capital Partners first reported a position in United Therapeutics in Q3 2023 and held it in 2 quarters.
  • Garda Capital Partners's United Therapeutics position peaked at $548K in Q4 2023.
  • 526 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2024.

Based on Garda Capital Partners's 13F filing for Q1 2024, filed 14 May 2024.